Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Collegium Pharma (COLL)

Collegium Pharma (COLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Collegium Pharma 100 Technology Center Drive Stoughton MA 02072 USA

www.collegiumpharma.com P: 781-713-3699 F: 781-828-4697

Description:

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States.

Key Statistics

Overview:

Market Capitalization, $K 1,160,409
Enterprise Value, $K 1,326,499
Shares Outstanding, K 32,706
Annual Sales, $ 566,770 K
Annual Net Income, $ 48,160 K
Last Quarter Sales, $ 149,750 K
Last Quarter Net Income, $ 31,940 K
EBIT, $ 166,960 K
EBITDA, $ 314,980 K
60-Month Beta 1.03
% of Insider Shareholders 3.98%
Float, K 31,404
% Float 96.02%
Short Volume Ratio 0.51

Growth:

1-Year Return 57.33%
3-Year Return 60.72%
5-Year Return 156.55%
5-Year Revenue Growth 102.12%
5-Year Earnings Growth 519.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.58 on 02/22/24
Latest Earnings Date 05/02/24
Earnings Per Share ttm 4.97
EPS Growth vs. Prev Qtr 19.83%
EPS Growth vs. Prev Year 47.96%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

COLL Ratios

Ratio
Price/Earnings ttm 7.23
Price/Earnings forward 6.17
Price/Earnings to Growth N/A
Return-on-Equity % 107.39%
Return-on-Assets % 17.07%
Profit Margin % 8.50%
Debt/Equity 2.07
Price/Sales 2.07
Price/Cash Flow 3.23
Price/Book 5.80
Book Value/Share 5.99
Interest Coverage -1.91
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar